Published February 2, 2022
| Version v1
Journal article
Open
Childhood Height Growth Rate Association with the Risk of Islet Autoimmunity and Development of Type 1 Diabetes
Authors/Creators
- 1. Center for Computational Health, IBM T.J. Watson Research Center, Cambridge and Yorktown Heights, MA and NY, USA
- 2. Department of Pediatrics, PEDEGO Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland
- 3. JDRF, New York, NY, USA
- 4. Barbara Davis Center for Diabetes, University of Colorado, Denver, CO, USA
- 5. Department of Virology, Faculty of Medicine and Health Technology, Tampere University, and Fimlab Laboratories, Pirkanmaa Hospital District, Tampere Finland
- 6. Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany der TU München, Munich, Germany, Forschergruppe Diabetes e.V. at Helmholtz Zentrum, Munich, Germany, Forschergruppe Diabetes, Technical University Munich, Germany
- 7. Pacific Northwest Research Institute, Seattle, WA, USA
- 8. Department of Clinical Sciences, Lund University Diabetes Center, Malmö, Sweden, Department of Pediatrics, Kristianstad Hospital, Kristianstad, Sweden
- 9. Department of Clinical Sciences, Lund University Diabetes Center, Malmö, Sweden
- 10. Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland
- 11. Center for Computational Health at IBM Research, JDRF and DAISY, DiPiS, DIPP, DEW-IT, BABYDIAB study sites
Description
Supplement for Childhood Height Growth Rate Association with the Risk of Islet Autoimmunity and Development of Type 1 Diabetes
Notes
Type 1 Diabetes, Autoantibodies, Prospective-cohort, Child Growth
Funding: This work was supported by funding from JDRF (IBM: 1-RSC-2017-368-I-X, 1-IND-2019-717-I-X), (DAISY: 1-SRA-2019-722-I-X, 1-RSC-2017-517-I-X, 5-ECR-2017-388-A-N), (DiPiS: 1-SRA-2019-720-I-X, 1-RSC-2017-526-I-X), (DIPP: 1-RSC-2018-555-I-X), (DEW-IT: 1-SRA-2019-719-I-X, 1-RSC-2017-516-I-X) as well as NIH (DAISY: DK032493, DK032083, DK104351; DiPiS: DK26190 and the CDC (DEW-IT: UR6/CCU017247).
The DIPP study was funded by JDRF (grants 1-SRA-2016-342-M-R, 1-SRA-2019-732-M-B); European Union (grant BMH4-CT98-3314); Novo Nordisk Foundation; Academy of Finland (Decision No 292538 and Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012-2017, Decision No. 250114); Special Research Funds for University Hospitals in Finland; Diabetes Research Foundation, Finland; and Sigrid Juselius Foundation, Finland.
The BABYDIAB study was funded by the German Federal Ministry of Education and Research to the German Center for Diabetes Research.
The DiPiS study was funded by Swedish Research Council (grant no. 14064), Swedish Childhood Diabetes Foundation, Swedish Diabetes Association, Nordisk Insulin Fund, SUS funds, Lion Club International, district 101-S, The royal Physiographic society, Skåne County Council Foundation for Research and Development as well as LUDC-IRC/EXODIAB funding from the Swedish foundation for strategic research (Dnr IRC15-0067) and Swedish research council (Dnr 2009-1039).
Additional funding for DEW-IT was provided by the Hussman Foundation and by the Washington State Life Science Discovery Fund.